Zoetis Inc. (ZTS)
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share.
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
Zoetis Inc. (ZTS) Q4 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Steve Frank - IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Russell Yuen - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Glen Santangelo - Jefferies Navann Ty - BNP Paribas Chris LoBianco - TD Securities Andrea Alfonso - UBS Daniel Clark - Leerink Partners Operator Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Why Zoetis Stock Was Falling Today
Shares of Zoetis (ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter.
Zoetis Earnings Top Analysts' Forecasts
Zoetis (ZTS -8.79%), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded the consensus estimate of $1.36.
Zoetis (ZTS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis (ZTS) Tops Q4 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.24 per share a year ago.
Zoetis forecasts 2025 profit, revenue below estimates; shares fall
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading.
Phibro Animal Health Is Cruising With Its Recent Zoetis Acquisition
Phibro Animal Health delivers animal health and nutritional solutions through feed additives, vaccines, and performance products. The Zoetis acquisition added 37 product lines, driving a 24% increase in net sales and 64% growth in adjusted EBITDA. The company projects strong revenue growth in 2025 with expanding margins and updated EPS guidance.
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Zoetis (ZTS) stood at $172.24, denoting a +0.17% change from the preceding trading day.
